Immunitas Therapeutics
Immunitas Therapeutics is a clinical-stage biotech developing first-in-class anti-CD161 antibodies (IMT-009, IMT-380) targeting the CD161-CLEC2D pathway for refractory solid tumors and autoimmune diseases, leveraging a single cell genomics drug discovery platform.
- Company typePrivate
- Founded2019
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Immunitas Therapeutics does
Immunitas Therapeutics is a clinical-stage biotechnology company founded in 2019 by cancer research and therapeutic antibody pioneers from Dana Farber Cancer Institute, Mass General Cancer Center, the Broad Institute, and MIT. The company is built on the identification of CD161 as a compelling T cell target in oncology and develops antibody-based therapeutics that modulate the CD161-CLEC2D pathway across oncology and autoimmune indications. Its lead program, IMT-009, is a first-in-class anti-CD161 monoclonal antibody currently in Phase 1/2a clinical development for refractory solid tumors, including microsatellite stable colorectal cancer, head and neck cancer, and non-small cell lung cancer, both as monotherapy and in combination with fruquintinib. A second program, IMT-380, is a preclinical anti-CD161 antibody targeting pathogenic T cells in autoimmune disease, and a third program explores a CLEC2D-TLR9 agonist conjugate.
The company's underlying technology combines a single cell analysis drug discovery platform with specialized expertise in the CD161-CLEC2D axis, enabling biomarker-driven patient stratification (e.g., tertiary lymphoid structures, KLRB1+ T cell abundance) and rational combination strategies with checkpoint inhibitors. Immunitas is incorporated in Massachusetts, headquartered in Waltham, and operates with 11–50 employees, supported by over $120 million in equity funding from a syndicate including Agent Capital, Alexandria Venture Investments, Evotec, Leaps by Bayer, Longwood Fund, M Ventures, Medical Excellence Capital, and Novartis Venture Fund.
As a pre-revenue biotech, Immunitas monetizes its pipeline primarily through licensing and milestone economics rather than product sales. Its commercial model relies on strategic partnerships to advance non-core programs — exemplified by the May 2026 global licensing agreement with Boehringer Ingelheim for a preclinical autoimmune antibody program, valued at up to €407.5 million in upfront and milestone payments plus tiered royalties — while retaining wholly owned development of IMT-009. Marketing reach is achieved through peer-reviewed publications and presentations at major scientific conferences (AACR, SITC, ASH, FASEB) rather than traditional sales channels.
Immunitas Therapeutics firmographics
Firmographics- Name
- Immunitas Therapeutics
- Legal name
- Immunitas Therapeutics, Inc.
- Website
- https://immunitastx.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Immunitas Therapeutics is a clinical-stage biotech developing first-in-class anti-CD161 antibodies (IMT-009, IMT-380) targeting the CD161-CLEC2D pathway for refractory solid tumors and autoimmune diseases, leveraging a single cell genomics drug discovery platform.
- Ownership category
- akta.pro rank
Immunitas Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Immunitas Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Immunitas Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Licensing and milestone payments: Immunitas receives upfront payments plus potential milestone payments and tiered royalties from licensing agreements. The Boehringer Ingelheim agreement includes an upfront payment plus potential milestone payments totaling up to €407.5 million, along with tiered royalties on future sales.
- Clinical development and approvals: Pre-revenue biotech company developing checkpoint inhibitors and antibody therapeutics through clinical trials toward regulatory approval and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Immunitas Therapeutics product offering
Product offeringCore offering
Immunitas Therapeutics is a clinical-stage biotechnology company developing antibody-based therapeutics targeting the CD161-CLEC2D pathway for oncology and autoimmune diseases. Its lead program IMT-009 is a first-in-class anti-CD161 monoclonal antibody in Phase 1/2a clinical trials for refractory solid tumors including MSS colorectal cancer, head and neck cancer, and non-small cell lung cancer. A second program, IMT-380, is a preclinical anti-CD161 antibody targeting pathogenic T cells in autoimmune diseases, with additional preclinical work on a CLEC2D-TLR9 agonist conjugate.
Product overview
Immunitas Therapeutics is developing a pipeline of differentiated immuno-oncology and autoimmune antibody-based therapeutics targeting the CD161-CLEC2D pathway. The company's lead program is IMT-009, a first-in-class anti-CD161 monoclonal antibody currently in Phase 1/2a clinical trials for solid tumors including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. The second program, IMT-380, is a preclinical first-in-class anti-CD161 antibody targeting pathogenic T cells for autoimmune diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- IMT-009 A first-in-class anti-CD161 monoclonal antibody in Phase 1/2a clinical trials for patients with refractory solid tumors, including MSS Colorectal Cancer, Head and Neck Cancer, and Non-Small Cell Lung Cancer. IMT-009 blocks the interaction of CD161 with its ligand CLEC2D, reinvigorating T and NK cell function and anti-tumor efficacy.
- IMT-380 A first-in-class anti-CD161 antibody targeting pathogenic T cells for the treatment of autoimmune diseases, building on the company's specialized knowledge of the CD161-CLEC2D pathway. Currently in preclinical development.
Quantifiable outcome
- Confirmed partial responses in MSS colorectal cancer patients as monotherapy and in combination with fruquintinib
- +2 more outcomes
Companies that use Immunitas Therapeutics
Customer profileSegments3 records
Ideal customer profiles2 records
Immunitas Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Immunitas Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boehringer IngelheimcoreGlobal licensing agreement for a preclinical antibody program targeting chronic inflammatory and autoimmune diseases. Boehringer Ingelheim obtains worldwide rights to develop, manufacture, and commercialize the program. Immunitas receives upfront payment plus potential milestone payments totaling up to €407.5 million, along with tiered royalties on future sales. The agreement expands Boehringer's immunology pipeline and enables Immunitas to advance its novel therapeutic into clinical development with a partner possessing global drug development expertise.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Immunitas Therapeutics competitors and assessment
Company assessmentDirect peers
- Cullinan Oncology: Clinical-stage oncology biotech developing differentiated therapeutics across multiple modalities (small molecules, antibodies). Comparable in size, clinical stage, and pipeline breadth approach to Immunitas.
- CytomX Therapeutics: Clinical-stage biotech developing Probody antibody platforms for tumor-selective activation in oncology. Comparable to Immunitas in pioneering novel antibody therapeutic approaches and targeting novel IO mechanisms in solid tumors.
- AnaptysBio: Clinical-stage immunology antibody company developing therapeutics for inflammatory and autoimmune diseases and immuno-oncology. Comparable to Immunitas given overlap in autoimmune antibody pipeline focus (similar therapeutic areas to IMT-380).
- Inhibrx (acquired by Sanofi): Was a clinical-stage biotech developing differentiated antibody therapeutics including novel immuno-oncology and rare disease assets before being acquired by Sanofi. Comparable to Immunitas in clinical-stage antibody therapeutic development and pipeline depth.
- Werewolf Therapeutics: Clinical-stage immuno-oncology biotech developing novel PREDATOR platform-based therapies with INDUKINE conditional activators. Comparable to Immunitas as a similarly sized clinical-stage IO company targeting novel immune checkpoints/tumor microenvironments in solid tumors.
- NextCure: Clinical-stage immuno-oncology company developing novel antibody therapeutics (NC318, NC410, LNCB74) targeting novel immune checkpoints including Siglec-15 and B7-H4. Closely comparable to Immunitas in size, stage, and approach — novel antibody IO assets in early-stage clinical trials.
- Compugen: Clinical-stage computational-immuno-oncology company discovering novel drug targets (PVRIG, TIGIT) using a proprietary predictive platform. Comparable to Immunitas in novel IO target identification, single-cell informed discovery, and clinical-stage antibody therapeutic focus.
- Adagene: Clinical-stage immuno-oncology company using POWERbody and SAFEbody platforms to engineer conditionally activated antibodies for novel targets. Similar to Immunitas in developing differentiated antibody therapeutics targeting novel immune checkpoints in oncology.
- Jounce Therapeutics: Clinical-stage immuno-oncology biotech focused on novel antibody therapeutics targeting immune checkpoints and myeloid cell biology. Comparable to Immunitas as a similarly sized, clinical-stage IO antibody company with pipeline built around novel IO mechanisms.
- Innate Pharma: Clinical-stage immuno-oncology company developing NK cell-based and antibody-based therapeutics, including anti-CD161/NKCE programs. Highly comparable given CD161 biology overlap with Immunitas' lead target and similar antibody-based IO pipeline.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Immunitas Therapeutics social profiles
Digital presenceImmunitas Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunitas Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
Immunitas Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunitas Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunitas Therapeutics
What does Immunitas Therapeutics do?
Immunitas Therapeutics is a clinical-stage biotechnology company developing antibody-based therapeutics targeting the CD161-CLEC2D pathway for oncology and autoimmune diseases. Its lead program IMT-009 is a first-in-class anti-CD161 monoclonal antibody in Phase 1/2a clinical trials for refractory solid tumors including MSS colorectal cancer, head and neck cancer, and non-small cell lung cancer. A second program, IMT-380, is a preclinical anti-CD161 antibody targeting pathogenic T cells in autoimmune diseases, with additional preclinical work on a CLEC2D-TLR9 agonist conjugate.
Is Immunitas Therapeutics a public or private company?
Immunitas Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Immunitas Therapeutics founded?
Immunitas Therapeutics was founded in 2019. It employs 11 to 50 people.
Where is Immunitas Therapeutics based?
Immunitas Therapeutics is headquartered in Cambridge, United States, in the North America region.
How does Immunitas Therapeutics make money?
Two revenue lines are on record. Licensing and milestone payments are the primary driver. The others are clinical development and approvals.
Who are Immunitas Therapeutics's main competitors?
Direct peers on record are Cullinan Oncology, CytomX Therapeutics, AnaptysBio, Inhibrx (acquired by Sanofi), Werewolf Therapeutics, NextCure, Compugen, Adagene, Jounce Therapeutics and Innate Pharma.
Does Immunitas Therapeutics have an API?
No public API is recorded for Immunitas Therapeutics.
What industry is Immunitas Therapeutics in?
Immunitas Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325413 and its SIC code is 2836.